Synmosa Biopharma Ransomware Attack by DragonForce (Apr 2026)

Claim Summary

On April 26, 2026, the ransomware group DragonForce allegedly added Synmosa Biopharma Corporation to its dark web leak site. The threat actor claims to have successfully breached the Taiwan-based specialty pharmaceutical company, which operates under the domain synmosa.com.tw. According to the leak site post, DragonForce asserts that it has exfiltrated data from Synmosa, though the volume and nature of the alleged stolen information remain undisclosed. The group’s description of the victim includes details about Synmosa’s operations as an agent, manufacturer, OEM, and R&D entity in the pharmaceutical sector, suggesting the threat actor conducted reconnaissance prior to the attack. This claim has not been independently verified, and no official confirmation from Synmosa Biopharma has been issued at the time of this report.

Threat Actor Profile

DragonForce is a ransomware group with a known track record of 431 claimed victims across various sectors globally. The group’s credibility is moderate, as it has demonstrated operational consistency but lacks extensive public research or attribution to specific advanced persistent threat (APT) groups. DragonForce’s known toolset includes:

• Mimikatz: Used for credential dumping from Windows systems.
• Advanced IP Scanner: Network discovery tool for identifying active hosts.
• PingCastle: Active Directory security auditing tool, often misused for privilege escalation.
• SoftPerfect NetScan: Network scanning utility for reconnaissance.

These tools indicate a focus on lateral movement and privilege escalation within compromised environments. DragonForce typically employs double extortion tactics, threatening to leak stolen data unless a ransom is paid. The group’s operational security posture suggests a moderate level of sophistication, though no YARA rules or specific detection guidance are publicly available for this group at this time.

Alleged Data Exposure

DragonForce claims to have accessed Synmosa Biopharma’s internal systems, but the specific data types allegedly compromised have not been detailed. Given Synmosa’s role in pharmaceutical manufacturing, OEM, and R&D, potential data exposure could include:

• Proprietary drug formulations and research data.
• Patient or clinical trial information (if applicable).
• Employee records and internal communications.
• Financial documents and supply chain contracts.

The lack of data volume disclosure may indicate either a limited breach or the group’s strategy to withhold details to pressure the victim. No samples or screenshots have been released to substantiate the claim.

Potential Impact

If verified, this incident could have significant consequences for Synmosa Biopharma and the broader healthcare supply chain in Taiwan:

• Regulatory Risk: Potential violations of Taiwan’s Personal Data Protection Act (PDPA) and international healthcare data regulations.
• Operational Disruption: Ransomware encryption could disrupt manufacturing, R&D, and distribution of pharmaceuticals.
• Reputational Harm: Loss of trust among partners, clients, and patients.
• Intellectual Property Theft: Exposure of proprietary drug formulas could harm competitive advantage.

The healthcare sector remains a high-value target for ransomware groups due to the critical nature of its operations and sensitive data.

What to Watch For

• Official Statement: Monitor Synmosa Biopharma’s website and press releases for confirmation or denial of the breach.
• Leak Site Activity: DragonForce may release additional details or data samples to escalate pressure.
• Regulatory Notices: Watch for filings with Taiwan’s data protection authority or healthcare regulators.
• Third-Party Alerts: Partners and clients may receive notifications if data is confirmed compromised.

Disclaimer

This report is based on unverified claims made by the DragonForce ransomware group on its dark web leak site. Yazoul Security has not independently confirmed the breach, the extent of data exposure, or the validity of the threat actor’s assertions. Ransomware groups frequently exaggerate or fabricate claims to coerce victims into payment. All information herein should be treated as preliminary and subject to change upon official verification. No PII, download links, or access credentials are provided in this report.